Bringing together 60+ senior leaders from large pharma, innovative biotech, academia and investment companies, this conference will discuss data-driven and solution-based approaches that focus on developing high value clinical candidates, […]
As AMR emerges, new strategies for the treatment of infection and identification of resistant microbes are crucial. This JPIAMR activity, led by the UK Medical Research Council (MRC) with support […]
The COMBINE project is part of the IMI AMR Accelerator. One of the scientific aims of COMBINE is to improve and standardize the pneumonia animal model used in AMR research […]
This live webinar will discuss the following topics: Are CMC and formulation efforts treated as the foster child in the innovation and development armament? Underestimating CMC and formulation aspects can […]
This webinar provided a unique opportunity for the antibiotic community. The Innovative Medicines Initiative's GNA NOW Consortium was looking for a novel antibiotic compound to progress to a clinical candidate […]
This webinar will cover the use of knowledge management tools in the IMI AMR Accelerator and how these can be used to both enhance data analysis workflows and also […]
GNA NOW Open Call webinar II This webinar provided a unique opportunity for the antibiotic community. The Innovative Medicines Initiative’s GNA NOW Consortium was looking for a novel antibiotic compound […]
New clinical trial designs for evaluation of antimicrobial agents Speakers: David Paterson, Director, University of Queensland Centre for Clinical Research (Australia) Julie Marsh, Biostatistical Lead, Wesfarmers Centre of Vaccines and […]
This workshop will explore combination therapy, from treatment to diagnostics. This will be a hands-on workshop with lectures and ample time for discussions. This workshop will be held online and […]
GARDP organises a live webinar that will feature presentations on the following topics: – The AMR Studio: a multidisciplinary podcast on antimicrobial resistance (Eva Garmendia) – Resources by the British […]
